← Leaderboards
Brian H. Johnston
Somagenics, Inc.
$13,080,722
Attributed
$13,080,722
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$13,080,722 · 14
By mechanism
R44$10,161,974 · 4
R43$2,918,748 · 10
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Small Hairpin Rna”
- Scott W Lowe · Sloan-Kettering Inst Can Research$16,984,930
- Norbert Perrimon · Harvard Medical School$16,486,965
- Todd R. Golub · Dana-Farber Cancer Institute$13,622,512
- Mark A Kay · Stanford University$13,314,059
- Scott Powers · Amplicon Corporation$13,131,889
- Brenton R Graveley · University Of Connecticut Sch Of Med/Dnt$12,486,218
Research focus
Small Hairpin RnaRna InterferenceBaseSuccessHepatitis CLeadInhibitor/AntagonistMouse ModelModificationProgramsDesignPharmaceutical PreparationsCollaborationsLiverIn VivoNovel StrategiesViralInfectionEfficacy TestingVirusHepatitis C VirusChronicSiteGenome
Grant awards (22)
Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus$965,488
R44 · FY2020 · AI · contact PI
Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus$1,000,000
R44 · FY2019 · AI · contact PI
A novel sshRNA-antimiR combination therapy for accelerating healing of diabetic foot ulcers$299,985
R43 · FY2019 · DK · contact PI
Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus$902,942
R44 · FY2018 · AI · contact PI
Accelerating Wound Healing through RNAi$683,474
R44 · FY2015 · GM · contact PI
Accelerating Wound Healing through RNAi$723,483
R44 · FY2014 · GM · contact PI
Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Viru$389,582
R43 · FY2014 · AI · contact PI
Chemical Stabilization of shRNAs and their development as hepatitis C drugs$783,579
R44 · FY2013 · AI · contact PI
Chemical Stabilization of shRNAs and their development as hepatitis C drugs$970,401
R44 · FY2012 · AI · contact PI
Accelerating Wound Healing Using RNAi$347,447
R43 · FY2012 · GM · contact PI
Chemical Stabilization of shRNAs and their development as hepatitis C drugs$1,000,000
R44 · FY2011 · AI · contact PI
An RNAi Trojan Horse for treatment of hepatitis C.$300,000
R43 · FY2009 · AI · contact PI
An RNAi Trojan Horse for treatment of hepatitis C.$295,743
R43 · FY2008 · AI · contact PI
Inhibition of hepatitis C by RNA-based therapeutics$1,021,558
R44 · FY2007 · AI · contact PI
Chemical stabilization of shRNAs for therpeutic use$165,648
R43 · FY2007 · AI · contact PI
Inhibition of hepatitis C by RNA-based therapeutics$1,279,170
R44 · FY2006 · AI · contact PI
Improved Delivery Methods for Small Interfering RNAs$297,420
R43 · FY2006 · GM · contact PI
RNAi-based inhibitors of stat3 for psoriasis treatment$195,967
R43 · FY2006 · AR · contact PI
Inhibition of hepatitis C by RNA-based therapeutics$831,879
R44 · FY2005 · AI
Treatment of multiple sclerosis model with RNA padlocks$276,966
R43 · FY2003 · NS
METHOD FOR DEVELOPING IMPROVED GENE INHIBITORS$171,300
R43 · FY2001 · GM
REGULATABLE INHIBITION OF ANY GENE IN TRANSGENIC MICE$178,690
R43 · FY2000 · GM